FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

2.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

3.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

4.

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

5.

Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot